1 Title

2 Co-development of gut microbial metabolism and visual neural circuitry in human infants

3

4 Authors

- 5 Kevin S. Bonham
- 6 Emma T. Margolis
- 7 Guilherme Fahur Bottino
- 8 Fadheela Patel
- 9 Shelley McCann
- 10 Michal R. Zieff
- 11 Kirsty A. Donald
- 12 Laurel J. Gabard-Durnam*
- 13 Vanja Klepac-Ceraj*
- 14

15 ORCID numbers:

- 16 Kevin S. Bonham: 0000-0003-3200-7533 17 Guilherme Fahur Bottino: 0000-0003-1953-1576 18 Emma T. Margolis: 0000-0002-2036-8078 19 Fadheela Patel: 0000-0001-5177-7416 20 Michal Zieff: 0000-0001-9352-9947 21 Shelley McCann: 0000-0002-9753-7968 22 Kirsten A. Donald: 0000-0002-0276-9660 23 Laurel J. Gabard-Durnam 0000-0002-4564-8068 24 Vanja Klepac-Ceraj: 0000-0001-5387-5706
- 25 26
- 27 Running title: Infant gut microbiome associates with visual neurodevelopment
- 28

29 Abstract

- 30 Infancy is a time of rapid brain development supporting foundational sensory learning. The gut
- 31 microbiome, also undergoing extensive developmental changes in early life, may influence brain
- 32 development through metabolism of neuroactive compounds. Here, we show across the first 18
- 33 months of life that microbial genes encoding enzymes that produce and degrade neuroactive
- 34 compounds, including neurotransmitters GABA and glutamate, the amino acid tryptophan, and
- 35 short-chain fatty acids including acetate and butyrate, are associated with visual
- 36 neurodevelopmental learning, measured by the visual-evoked potential (VEP). Microbial gene
- 37 sets from stool collected around 4 months of age were strongly associated with VEP features
- 38 measured from 9 to 14 months of age and showed more associations than concurrently
- 39 measured gene sets, suggesting microbial metabolism in early life may have long term effects
- 40 on neural plasticity and development.

41 Introduction

42 The gut microbiome in early life has potential long-term implications for brain and body health. 43 One important way this influence can occur is through interactions with the central nervous 44 system as a "microbial-gut-brain-axis" (Rhee, Pothoulakis, and Mayer 2009; Collins, Surette, 45 and Bercik 2012). The metabolic potential of the microorganisms that inhabit the gut vastly 46 exceeds that of human cells alone, with microbial genes outnumbering host genes by a 47 hundredfold (Gilbert et al. 2018). In particular, gut microbes have the ability to metabolize and 48 synthesize many neuroactive compounds (Valles-Colomer et al. 2019). Extensive work in 49 preclinical models suggests that these neuroactive compounds can influence the brain through both direct and indirect routes. For example, major neurotransmitters (e.g., glutamate, y-50 51 aminobutyric acid (GABA), serotonin, and dopamine) are readily synthesized and degraded by 52 intestinal microbes and can directly stimulate enteric nerve cells or enter circulation and pass 53 the blood-brain barrier to influence central nervous function (Janik et al. 2016; Ahmed et al. 54 2022). Glutamatergic/GABA-ergic signaling is critical for balancing the brain's excitatory and 55 inhibitory neurotransmission levels, and bi-directional glutamatergic/GABA-ergic signaling 56 between the gut microbiome and brain is implicated in several physical and mental health 57 conditions (Filpa et al. 2016; Baj et al. 2019). Similarly, the gut and the microbiome are critical to 58 the regulation of metabolism for the neurotransmitters serotonin and dopamine, particularly through the metabolism of dietary tryptophan (Agus, Planchais, and Sokol 2018). Moreover, 59 60 short-chain fatty acids (SCFAs) produced by the gut microbiome may impact the brain directly 61 by modulating neurotrophic factors, glial and microglial maturation, and neuroinflammation (Dalile et al. 2019; Erny et al. 2021). Other indirect pathways for gut microbial influence on the 62 63 brain include vagus nerve stimulation, neuroendocrine modulation and immune system

- 64 regulation (Rhee, Pothoulakis, and Mayer 2009).
- 65

66 Rapidly growing literature connects the metabolic potential of the gut microbiome and brain

67 function in humans (reviewed in (Ahmed et al. 2022; Parker, Fonseca, and Carding 2019;

Aburto and Cryan 2024)), however, the overwhelming majority of this research is performed in

adults. Importantly, both the gut microbiome and the brain undergo dramatic and rapid

development over the first postnatal years (Yassour et al. 2016; Bonham et al. 2023; Lippé et al.

2007; Dean et al. 2014). However, very little is currently known about how gut-brain influences

72 emerge or change during this critical window for both systems (Ahrens et al. 2024; Meyer et al.

73 2022). Interrogating this early co-development in humans is therefore key to both understanding

adaptive gut-brain function and behavior and informing strategies to support it. The visual cortex

has been shown to be sensitive to gut microbiome modulations in adults (Canipe, Sioda, and
Cheatham 2021) and in rodents (Lupori et al. 2022), yet the visual cortex undergoes its most

77 rapid period of plasticity and maturation over infancy when the microbiome changes most

representation can be significantly (Deen et al. 2017; Ellis et al. 2021; Kiorpes 2015). Visual cortical maturation can be

79 robustly indexed via EEG with the visual-evoked potential (VEP) response to visual stimuli from

80 birth. The VEP is especially useful for indexing visual neurodevelopment as its morphology

81 includes amplitude deflections and latencies to those deflections that reflect maturation of

82 function and structure, respectively.

84 Here, we investigated the co-development of microbial gene functional potential - specifically

85 genes encoding enzymes that metabolize neuroactive compounds - and visual

- 86 neurodevelopment as indexed by the VEP in a longitudinal community sample of 185 infants
- 87 from Gugulethu in Cape Town, South Africa recruited as part of an ongoing prospective study,
- called "Khula" (Zieff et al. 2024). Stool samples and EEG were collected at up to 3 visits in the
- 89 first 18 months of life. Shotgun metagenomic sequencing was used to obtain microbial gene
- 90 sequences from infant stool samples. To index visual cortical development, latencies and
- 91 amplitudes were extracted from each deflection component of the VEP (i.e., first negative-going
- 92 deflection, N1; first positive-going deflection, P1; and second negative-going deflection, N2),
- 93 producing six VEP features of interest. We evaluated the concurrent association between
- 94 microbial genes and VEP amplitudes and latencies and tested prospective influences of
- 95 microbial genes from early visits on VEP changes at later visits to reveal the temporal dynamics
- 96 of gut-brain co-development within individuals during this most critical window of plasticity.
- 97

98 Results

99 The brain and microbiome develop rapidly in the first months of life

100 To investigate the co-development of the gut microbiome and visual neurodevelopment, we

101 collected stool and measured VEP in a longitudinal cohort of 194 children in South Africa in the

first 18 months of life (Figure 1A, B, Table 1; visit 1, N = 119, age 3.6 ± 0.7 months, visit 2, N =

103 144, age 8.7 ± 1.4 months, visit 3, N = 130, age 14.2 ± 1.0 months). As expected for children at

this age (Koenig et al. 2011; Yassour et al. 2016; Bäckhed et al. 2015), the microbial
 composition was developmentally dependent, with the first principle coordinate axis for both

105 composition was developmentally dependent, with the first principle coordinate axis for both 106 taxonomic profiles (Figure 1C; variance explained = 15.1%; R = -0.50)) and functional profiles

107 (Figure 1D; variance explained = 12.9%; R = -0.57) driven strongly by the age of the subject at

108 the time of collection. Similarly, both amplitude and latency VEP features were also strongly

109 correlated with age, such that latencies (especially P1 and N2) became shorter, while the P1

- 10 became less positive and the N1 and 2 components became more negative in amplitude as
- 111 infants got older (Figure 1E).
- 112





114 Fig. 1: The gut microbiome and VEP both develop over the first 18 months of life.

(A) Study design; participants (N=194) were seen up to 3 times over the first 18 months of life.

116 Metagenomes and EEG data were collected, generating microbial functional profiles (stool) and VEP

117 waveforms (EEG) used in subsequent analyses. (B) Longitudinal sampling of study participants; Density

118 plots (top) for stool and EEG collection show the ages represented in each visit. The scatter plot (bottom)

119 shows individual participant visits. Dotted lines connect separate visits for the same participant. When

120 stool and EEG data were collected for the same visit (purple) but not on the same day, dot represents the

121 median age of collection, and vertical bars in blue and red represent stool and EEG collections

122 respectively. (C) Principal coordinate analysis (PCoA) by multidimensional scaling (MDS) on Bray-Curtis

123 dissimilarity of taxonomic profiles; percent variance explained (fraction of positive eigenvalues) by each of

the first two axes are indicated on the x and y axes respectively. (D) PCoA of microbial functional profiles

125 (UniRef90s). (E) Average VEP waveforms at each visit.

126

127 Microbial genes with neuroactive potential are associated with visual

128 development

129 To test whether microbial metabolic potential was related to early life brain activity, we

130 performed feature set enrichment analysis (FSEA) using groups of potentially neuroactive

131 microbial genes and the VEP amplitude and latency features (Bonham et al. 2023; Valles-

132 Colomer et al. 2019). For each gene set that had at least 5 genes represented in a given

133 comparison group, logistic regression was performed using VEP features as predictors and the

134 presence or absence of each microbial gene in the metagenome as the response to determine

135 concurrent associations (see Methods). Z statistics for in-set genes were compared to all genes

- 136 using a permutation test to determine significance of the associations as described in
- 137 (Subramanian et al. 2005). Of the 35 genesets assessed, 19 had sufficient representation to
- 138 test, and of those, 18 were significantly associated with at least one EEG feature during at least
- 139 one visit within the 18-month window after correcting for false discovery rate (Benjamini-
- 140 Hochberg, q < 0.2; Figure 2, Table 2). Microbial genes involved in synthesis or degradation of
- 141 molecules with neuroactive potential were associated with both VEP amplitudes or latencies at
- 142 each visit, demonstrating widespread associations between early life gut microbiome and visual
- 143 cortex neurodevelopment. The number of these associations increased over time (visit 1 had 6
- associations, visit 2 had 24, and visit 3 had 37), which could reflect the fact that *in utero*
- 145 development is thought to occur in a sterile environment, providing less opportunity for microbial
- 146 metabolism to influence visual cortex development in the first 3 months of life.



148 Fig. 2: Concurrent feature set enrichment analysis of microbial neuroactive genes and VEP for 149 three visits.

FSEA results for all genesets where at least one visit had a significant hit (q < 0.2) with at least one VEP latency (A) or amplitude (B). Dots indicate the Z-statistic from logistic regression for each gene in a gene set. Vertical bars indicate the median Z-statistic for the gene set as a whole. Y-axis position for each gene set indicates visit number. Visit 1 for inositol degradation and DOPAC synthesis were not tested, since there were fewer than 5 genes from those genesets present in the sample (See Methods).

155

- 156 Specifically, across the gene sets involved in neurotransmitter synthesis and degradation,
- 157 glutamate synthesis showed robust associations with all VEP features, primarily at the 3rd visit
- 158 (mean age 14.3 months), while glutamate degradation was weakly but significantly associated
- 159 only with the amplitude of N2 at visit 3. GABA synthesis was also associated with the latency of
- 160 the P1 peak at visit 1 (mean age 3.6 months). The regulation of this balance between glutamate
- 161 and GABA (i.e., excitatory/inhibitory balance) is important for modulating neuroplasticity in the
- 162 visual cortex during infancy (Fagiolini and Hensch 2000; Hensch et al. 1998), and suggests that
- 163 microbial metabolism is related to the VEP as an index of this changing neuroplasticity. Gene

sets involved in tryptophan metabolism, which is linked to the metabolism of the

- 165 neurotransmitter serotonin as well as other neuroactive molecules such as kynurenine (Agus,
- 166 Planchais, and Sokol 2018) was associated with VEP latencies of P1 at visit 1, N1 and P1 at
- 167 visit 2, and N2 at visit 3. The degradation of quinolinic acid, also downstream of tryptophan
- 168 metabolism, was negatively enriched in children with shorter P1 latency at visit 1 and smaller P1
- amplitude at visit 3, while the synthesis of quinolinic acid was positively associated with the
- amplitude of the N2 peak at visit 1. Serotonin is a key regulator of other neurotransmitters, while
- 171 quinolinic acid is part of the kynurenine pathway and is a neurotoxin that can cause neuronal
- dysfunction, but may also play a role in glutamate uptake in the brain (Lugo-Huitrón et al. 2013;
- 173 Tavares et al. 2000).
- 174

175 Amongst the short-chain fatty acid (SCFA) metabolizing gene sets tested, acetate synthesis 176 was strongly associated with all VEP features except N1 amplitude at visit 3, and also with N2 177 latency at visit 2. Propionate degradation was significantly associated with VEP latencies at 178 every visit over the 18-month window (N1 at visits 1 and 2, and both P1 and N2 at visit 3), as 179 well as with the amplitude of N1 at visit 3, while propionate synthesis was negatively associated 180 with N1 latency at visit 1 and positively associated with N2 amplitude at visit 3. Butyrate 181 synthesis is also associated with P1 and N2 latencies at visit 2, and with their amplitudes at visit 182 3. SCFAs play important roles in immune regulation, including neuroinflammation. Propionate is widely regarded as neuroprotective, having indirect effects on the CNS by regulating 183 inflammatory responses and stimulating the release of GLP-1 from neuroendocrine cells in the 184 gut epithelium, while circulating butyrate increases myelination (Chen et al. 2019). Finally, 185 186 within the remaining gene sets tested, we observed robust associations in particular between 187 menaguinone (Vitamin K2) gene sets and the VEP features over this infancy window. This is 188 reassuring as vitamin K2 specifically is posited to promote healthy vision both outside of the brain through effects on the retina and within the brain where it can protect neural circuits from 189 190 oxidative stress (Li et al. 2003). Notably, across significant gene set associations with VEP 191 features, the P1 and N2 component amplitudes and latencies were consistently the most 192 sensitive to these microbial gene sets. Both P1 and N2 components are known to show the most dramatic changes with development during the first year of life and may best reflect 193 194 underlying visual learning and plasticity at this stage.

195 Microbial metabolic potential predicts future brain development in infancy

196 Given that differences in metabolic potential of the early life microbiome may exert their effects

197 over time, we sought to determine whether microbial genes at early time points were associated

198 with subsequent VEP development. To investigate this, we performed FSEA on stool samples

collected at visit 1 with VEP measured at visit 2 (age at stool collection = 3.6 ± 0.8 months, age at VEP = 8.6 ± 1.5 months) or visit 3 (age at stool collection = 3.7 ± 0.7 months, age at VEP =

 14.1 ± 1.1 months), as well as visit 2 stool samples with visit 3 VEP (age at stool collection = 8.9

202 \pm 1.5 months, age at VEP = 14.3 \pm 1.0 months) (Figure 3A). All gene sets except DOPAC

synthesis that had a significant hit with concurrently measured VEP were also significantly

associated with at least one future VEP feature (Figure 3B, Tables 2-5). Notably, the quantity of

those associations increased substantially for all longitudinal comparisons compared to

206 concurrent ones. For example, only 6 microbial gene sets were associated with visit 1 VEP, and

each of those was only associated with a single concurrently measured VEP feature. By
contrast, 13 visit 1 gene sets were associated with visit 2 VEP features, and 11 were associated
with visit 3 VEP features, the majority (9/13 for visit 2, 8/11 for visit 3) were associated with at
least 2 VEP features, and nearly half (6/13 for visit 2, 5/11 for visit 3) were associated with more
than 2.

212





(A) Age distributions for stool samples (left) and VEP (right) for each longitudinal comparison (same individual) tested, V1 stool $Z \rightarrow V2$ VEP, V1 stool $\rightarrow V3$ VEP, and V2 stool $\rightarrow V3$ VEP. As in Figure 2, (B) and (C) show FSEA results for all genesets where at least one visit had a significant hit (q < 0.2) with at least

217 (C) show FSEA results for all genesets where at least one visit had a significant fill (q < 0.2) with at least 219 are VED latency or explicitly because the Z statistic from logistic representation for each

- one VEP latency or amplitude respectively. Dots indicate the Z-statistic from logistic regression for each
- gene in a gene set. Vertical bars indicate the median Z-statistic for the gene set as a whole. The Y-axis position for each gene set indicates longitudinal comparison. V1 \rightarrow V2 and V1 \rightarrow 3 for inositol
- degradation and DOPAC synthesis were not tested, since there were fewer than 5 genes from those
- 222 genesets present in the sample (See Methods).

224 Table 2: Longitudinal FSEA, visit 1 stool -> visit 2 VEP

Gene set	Feature type	Peak	Enrichment	Q value
GABA synthesis	amp	P1	-0.3987298838	0.08078918919
		N2	0.3661036051	0.1129448276
	latency	N1	-0.2829156583	0.04452
Glutamate synthesis		P1	0.2625066112	0.08078918919
	amp	P1	0.2316538042	0.1023130435
		P1	0.3369665011	0.1598153846
Glutamate degradation	latency	N2	0.3252682367	0.1800808989
	amp	P1	0.3256631998	0.1760093023
		N1	-0.2211303459	0.02725714286
	latency	P1	0.1671470069	0.08078918919
Tryptophan synthesis		N2	0.1900183195	0.04845714286
	amp	N2	-0.1630723325	0.1023130435
Quinolinic acid synthesis	amp	N1	-0.2735268422	0.1609156627
	1	P1	0.1979735587	0.1023130435
Quinolinic acid degradation	latency	N2	0.1950682309	0.1118888889
		N1	-0.2190895918	0.02935384615
Acetate synthesis	latency	P1	0.1926523891	0.06115384615
		N2	0.2157444594	0.0318
	amp	P1	0.1860132394	0.0742
		N2	-0.1960332174	0.05492727273
Butyrate synthesis	amp	N1	-0.3193476197	0.1698494118
	latency	N1	0.2711007176	0.1223076923
Isovaleric acid synthesis	amp	N1	0.2412188311	0.1800808989
		P1	-0.2409522895	0.1609156627
Menaquinone synthesis	latency	N1	-0.1393490274	0.1598153846
	amp	N1	-0.4295268274	0.1804304348
Inositol synthesis	latency	N1	-0.4219126859	0.1834357895
p-Cresol synthesis	amp	N1	-0.3665789266	0.1825935484
		P1	0.452086746	0.1014571429
		N2	-0.5164507055	0.04452
17-beta-Estradiol degradation	latency	N2	0.3550449716	0.1800808989

226	
227	
228	

229 Table 3: Longitudinal FSEA, visit 1 stool -> visit 3 VEP

230

Gene set	Feature type	Peak	Enrichment	Q value
GABA synthesis	latency	P1	0.4343386934	0.04452
	amp	P1	0.4099001639	0.0742
		N2	-0.5065759161	0.02544
Glutamate synthesis	latency	N1	-0.3035011084	0.02935384615
	amp	N1	-0.2344054782	0.1118888889
	latency	N1	-0.1875306139	0.04452
l ryptophan synthesis	amp	P1	-0.2176124281	0.0159
	latency	P1	-0.1862809727	0.109392
Quinolinic acid degradation		N2	-0.2624478514	0.1834357895
	amp	P1	-0.1689430121	0.1609156627
Acetate synthesis	latency	N1	-0.1728769986	0.08078918919
Propionate synthesis	amp	P1	0.3586598762	0.08078918919
	latency	N1	-0.5097549612	0.109392
		P1	0.5345516637	0.08806153846
Propionate degradation	amp	P1	0.738806805	0
		N2	-0.6669122013	0.02725714286
Butyrate synthesis	latency	N1	0.3373261944	0.1223076923
		N2	-0.3232764867	0.1498520548
	amp	P1	0.368868764	0.1014571429
	latency	P1	0.1582676302	0.08703157895
Menaquinone synthesis	amp	N1	-0.1417486481	0.1397408451
		P1	0.1488038682	0.1131864407
		N2	-0.1567020165	0.1023130435
Inositol synthesis	amp	N2	-0.4538038427	0.1210451613
СІрВ	latency	N1	-0.2835050435	0.1804304348
	amp	P1	-0.3284206328	0.1129448276
		N2	0.3585858703	0.08001290323

232 Table 4: Longitudinal FSEA, visit 2 stool -> visit 3 VEP

Gene set	Feature type	Peak	Enrichment	Q value
GABA synthesis	latency	N1	-0.3762158971	0.107325
	latency	N1	-0.1676219701	0.1609156627
Glutamate synthesis		P1	0.2979689116	0.0159
	amp	P1	0.23424529	0.03816
	latency	P1	0.3174180129	0.14045
Glutamate degradation	amp	N2	0.2829464416	0.187555102
Ta atophon overtheorie		N1	-0.1554890366	0.06083478261
Tryptophan synthesis	amp	P1	0.1865391121	0.02935384615
		N1	-0.3186382801	0.061056
Quinolinic acid synthesis	latency	P1	0.333137823	0.043725
	amp	P1	0.2577611214	0.1391826087
		N1	-0.1673242602	0.061056
	latency	P1	0.2574696731	0
Acetate synthesis		N2	-0.1373776916	0.1529837838
	amp	P1	0.1469554921	0.1210451613
Propionate synthesis	amp	P1	0.2994151994	0.1262363636
	latency	N1	-0.5503973578	0.0742
-		N2	0.4492537427	0.1609156627
Propionate degradation	amp	P1	0.5088146404	0.1118888889
		N2	-0.4229989983	0.187555102
	latency	N1	-0.3316428446	0.08078918919
Butyrate synthesis		P1	0.3335618515	0.0742
		N2	-0.2908124776	0.1223076923
	amp	N2	0.3066681625	0.1118888889
	latency	P1	0.2316852688	0.1556526316
Isovaleric acid synthesis	amp	P1	0.2469367892	0.1129448276
Menaquinone synthesis	latency	N1	0.1528795641	0.1210451613
	amp	N1	-0.1644331641	0.107325
		P1	0.2014568364	0.02935384615
		N2	-0.1634034966	0.1121672727
Inositol degradation	latency	N1	-0.6381259915	0.02935384615
		P1	0.5323381792	0.1014571429

	amp	P1	0.6413929993	0.02935384615
p-Cresol synthesis	latency	P1	0.3118799423	0.1397408451
		N2	-0.3152864697	0.1391826087
	amp	N1	-0.3039764673	0.1658142857
S-Adenosylmethionine synthesis	amp	N1	-0.2228894468	0.1556526316
		P1	0.2295724682	0.1347940299
17-beta-Estradiol degradation	amp	P1	0.2818613888	0.187555102
ClpB	latency	P1	0.2687857561	0.1804304348

- 234 Neurotransmitters GABA and glutamate, tryptophan metabolism (tryptophan and quinolinic acid)
- and SCFAs including menaquinone and acetate were all significantly associated with multiple
- 236 VEP features across multiple longitudinal comparisons.

237 Discussion

238 The past decade has seen a remarkable growth in our understanding of the relationships

- between the gut microbiome and the brain. However, a great deal of that investigation has
- 240 focused on neuropsychiatric disorders or atypical development, and animal models of those
- 241 disorders (e.g., autism spectrum disorder, depression/anxiety) have an unknown relationship to
- the human disorders that they represent, limiting their explanatory potential. A research program
- that investigates typical development using non-invasive measurements in humans, that is
- accurate and reproducible and shows variation in the first year of life, and that is directly
- 245 measurable in rodent models is sorely needed. The relationship between gut microbial
- 246 metabolism and VEP development offers just such a paradigm.
- 247

248 Here, we have shown a robust, prospective relationship between microbial genes involved in

- 249 the metabolism of neuroactive compounds and the development of visual response in the brain
- as measured by EEG. It is particularly encouraging that the microbial metabolism earlier in life is
- 251 more strongly associated with future measures of VEP than those collected concurrently. While
- 252 not dispositive, this would be the predicted outcome if microbial genes are causally influencing
- 253 brain development. It is also encouraging that the gene sets most associated with VEP
- 254 development are for the metabolism of molecules with known links to developmental
- 255 neuroplasticity and development of the visual cortex (Fagiolini and Hensch 2000; Hensch et al.
- 256 1998; Takesian et al. 2018).
- 257

Interestingly, the sign of several associations changes from one comparison to another. For
 example, acetate synthesis, tryptophan synthesis, and quinolinic acid degradation are all

- 260 positively associated with N2 latency when comparing visit 1 stool to visit 2 VEP, but negatively
- associated when comparing visit 2 stool to visit 3 VEP. The sign of tryptophan synthesis
- associations is particularly unstable; it is positively associated with P1 latency when comparing
- visit 1 or visit 2 stool to the following visit VEP, but negatively associated when comparing visit 1
- stool to visit 3 VEP, is negatively associated with P1 amplitude and N2 amplitude in one

comparison but positively associated in another. These results suggest that the impact of microbial metabolism on brain development may be context dependent.

267

268 One limitation of this study is the fact that we are only able to observe the genomic composition 269 of the microbiome, rather than the concentration of metabolites themselves. This prevents us 270 from determining the concentration of these molecules in the gastrointestinal tract, blood, and 271 brain, as the abundance of these genes does provide information about their activity, their 272 interactions with other metabolic pathways (including those of the host), or absorption by colonic 273 epithelial cells. Additionally, the relationship between gene abundance and molecule 274 concentration may be counterintuitive. For example, genes for breaking down a molecule may 275 be prevalent if that molecule is at high concentrations, or the molecules may be rapidly 276 degraded by other members of the community the moment they are produced. The balance of 277 degradation and synthesis occurs both at the individual organism level and at the community 278 level. This may also explain the somewhat puzzling results where some gene set / VEP feature 279 associations change from positive to negative association (or vice versa) when comparing 280 different timepoints. It may be that the relationship between metabolite and brain development 281 remains the same, while the relationship between molecules and microbial selection changes at 282 different stages of life. Addressing these limitations in humans is challenging, even if looking at stool metabolites, since overall exposure throughout the gastrointestinal tract is not necessarily 283 284 reflected in the final concentration of those molecules in stool. Therefore, metabolites from 285 blood plasma could provide more accurate systemic concentrations of molecules, but 286 challenges remain on how to interpret them (Deng et al. 2023; Dekkers et al. 2022). 287 288 Given that the VEP is evolutionarily conserved in mammals and can be accurately measured 289 during rodent development, the hypotheses generated in humans in this study are readily 290 testable using in vivo models. Germ free or defined-microbiome animals (Wymore Brand et al. 291 2015; Kennedy, King, and Baldridge 2018) may be supplemented with specific molecules such 292 as SCFAs, or colonized with microbial species lacking or providing specific metabolic pathways. 293 and molecule concentrations in tissues from the gut to the brain can be directly assessed. 294 Uncovering relationships between microbial metabolism and specific molecules may also 295 generate hypotheses that can be confirmed in human data. This study provides a foundation for

- 296 deep investigation of the relationships between the gut microbiome and brain development.
- 297
- 298

299 Materials and methods

300 Cohort, ethics, etc

301 Participants and Study Design

Infants were recruited from local community clinics in Gugulethu, an informal settlement, in Cape Town, South Africa as part of an ongoing longitudinal study (most of the enrollment happened prenatally with 39% of infants enrolled shortly after birth (Zieff et al. 2024)). The first language for the majority of residents in this area is Xhosa. Study procedures were offered in English or Xhosa depending on the language preference of the mother. This study was approved by the relevant

university Health Research Ethics Committees (University of Cape Town study number:
666/2021). Informed consent was collected from mothers on behalf of themself and their infants.
Demographic information including maternal place of birth, primary spoken language, maternal
age at enrollment, maternal educational attainment, and maternal income were collected at
enrollment (see Table 1).

312

Families were invited to participate in three in-lab study visits over their infant's first year and a half of life. At the first in-lab study visit (hereafter Visit 1), occurring when infants were between approximately 2 months and 6 months of age, the following data were collected: the infants' age (in months), sex, infant electroencephalography (EEG), and infant stool samples.

317

318 At the second study visit (hereafter Visit 2), occurring when infants were between approximately 319 6 months and 12 months of age (age in months: M=8.60, SD=1.48, range=5.41-12.00) and at 320 the third study visit (hereafter Visit 3), occurring when infants were between approximately 12 321 months and 17 months of age (age in months: M=14.10, SD=1.04, range=12.10-17.00), infant 322 EEG and stool samples were collected again. At visits in which infants were unable to complete 323 both EEG and stool samples on the same day, EEG and stool samples were collected on 324 different days. For concurrent time point analyses, infants with EEG and stool collected more 325 than two months apart were excluded. Not all infants had EEG and microbiome data collected at 326 all three timepoints or contributed usable data at all three timepoints. 327

328 All enrolled infants received a comprehensive medical exam at each visit, which included

assessments of eye-related conditions. Several infants (n=3) were identified as having eye-

related anomalies during the medical exam, and they were excluded from any further analyses.

331 EEG Processing

332 EEG Data Acquisition

333 Electroencephalography (EEG) data were acquired from infants while they were seated in their 334 caregiver's lap in a dimly-lit, quiet room using a 128-channel high density HydroCel Geodesic 335 Sensor Net (EGI, Eugene, OR), amplified with a NetAmps 400 high-input amplifier, and 336 recorded via an Electrical Geodesics, Inc. (EGI, Eugene, OR) system with a 1000 Hz sampling 337 rate. EEG data were online referenced to the vertex (channel Cz) through the EGI Netstation 338 software. Impedances were kept below 100K Ω in accordance with the impedance capabilities of 339 the high-impedance amplifiers. Geodesic Sensor Nets with modified tall pedestals designed for 340 improving inclusion of infants with thick/curly/tall hair were used as needed across participants 341 (Mlandu et al., 2024). Shea moisture leave-in castor oil conditioner was applied to hair across the scalp prior to net placement to improve both impedances and participant comfort (Mlandu et 342 343 al., 2024). This leave-in conditioner contains insulating ingredients so there is no risk of 344 electrical bridging and has not been found to disrupt the EEG signal during testing (unpublished 345 data). Conditioning hair in this way allows for nets to lay closer to the scalp for curly/coily hair 346 types and makes for far more comfortable net removal at the end of testing. 347

The Visual-Evoked Potential (VEP) task was presented using Eprime 3.0 software (Psychology
Software Tools, Pittsburgh, PA) on a Lenovo desktop computer with an external monitor 19.5
inches on the diagonal facing the infant (with monitor approximately 65 cm away from the
infant). A standard phase-reversal VEP was induced with a black and white checkerboard (1cm
x 1 cm squares within the board) stimulus that alternated presentation (black squares became
white, white squares became black) every 500 milliseconds for a total of 100 trials. Participant

looking was monitored by video and by an assistant throughout data collection. If the participant

looked away during the VEP task, the task was rerun.

356

357 EEG Data Pre-Processing

VEP data were exported from native Netstation .mff format to .raw format and then preprocessed using the HAPPE+ER pipeline within the HAPPE v3.3 software, an automated opensource EEG processing software validated for infant data (Monachino et al. 2022). A subset of the 128 channels were selected for pre-processing that excluded the rim electrodes as these are typically artifact-laden. The HAPPE pre-processing pipeline was run with user-selected specifications.

364

365 Pre-processed VEP data were considered usable and moved forward to VEP extraction if

366 HAPPE pre-processing ran successfully, at least 15 trials were retained following bad trial

- rejection, and at least one good channel was kept within the visual ROI. Note that channels marked bad during pre-processing had their data interpolated as part of standard pre-
- 369 processing pipelines for ERPs (Monachino et al. 2022). Interpolated channels were included in
- analyses here as is typically done in developmental samples and given the low overall rates of
- interpolation present (e.g., all groups at all visits had an average of between 4 to 5 of 5 possiblegood channels in the region of interest retained).
- 373

374 Visual-Evoked Potentials (VEPs)

375 VEP waveforms were extracted and guantified using the HAPPE+ER v3.3 GenerateERPs script 376 (Monachino et al. 2022). Electrodes in the occipital region were selected as a region of interest 377 (i.e., E70, E71, E75, E76, E83). The VEP waveform has three main components to be 378 guantified: a negative N1 peak, a positive P1 peak, and a negative N2 peak. Due to normative 379 maturation of the waveforms as infants age, one set of user-specified windows for calculating 380 component features was used for Visit 1 and 2 and another was used for Visit 3. For Visits 1 381 and 2, the window for calculating features for the N1 component was 40-100 ms, 75-175 ms for 382 the P1 component, and 100-325 ms for the N2 component. For Visit 3, the window for 383 calculating features for the N1 component was 35-80 ms, 75-130 ms for the P1 component, and 384 100-275 ms for the N2 component.

385

386 To correct for the potential influence of earlier components on later components, corrected

- amplitudes and latencies were calculated and used in all analyses. Specifically, the P1
- amplitude was corrected for the N1 amplitude (corrected P1 amplitude = P1 N1 amplitude); the
 P1 latency was corrected for the N1 latency (corrected P1 latency = P1 N1 latency); the N2
- amplitude was corrected for the P1 amplitude (corrected P1 latency = P1 N1 latency), the N2 amplitude was corrected for the P1 amplitude (corrected N2 amplitude = N2 P1 amplitude),
- and the N2 latency was corrected for the P1 latency (corrected N2 latency = N2 P1 latency).
- 392

All VEPs were visually inspected to ensure that the automatically extracted values were correct

and were adjusted if observable peaks occurred outside the automated window bounds.

395 Participants were considered to have failed this visual inspection and were subsequently

396 removed from the data set if their VEP did not produce three discernible peaks. VEP waveforms

of included participants by timepoint are included in Figure 1E. XX infants provided usable VEP

- data at Visit 1, XX infants provided usable VEP data at Visit 2, and XX infants provided usable
- 399 VEP data at Visit 3. There were no differences in EEG quality (i.e., number of trials collected,
- 400 number/percent of trials retained, number/percent of channels retained overall, number/percent
- 401 of channels retained in ROI) by time point (all p>.05).
- 402 Biospecimens and sequencing
- 403 Sample Collection

- 404 Stool samples were collected in the clinic by the research assistant directly from the diaper and
- transferred to the Zymo DNA/RNA Shield[™] Fecal collection Tube (#R1101, Zymo Research
- 406 Corp., Irvine, USA) and immediately frozen at -80 °C. Stool samples were not collected if the
- 407 subject had taken antibiotics within the two weeks prior to sampling.
- 408

409 **DNA Extraction**

- 410 DNA extraction was performed at Medical Microbiology, University of Cape Town, South Africa
- 411 from stool samples collected in DNA/RNA Shield™ Fecal collection tube using the Zymo
- 412 Research Fecal DNA MiniPrep kit (# D4003, Zymo Research Corp., Irvine, USA) following
- 413 manufacturer's protocol. To assess the extraction process's quality, ZymoBIOMICS® Microbial
- 414 Community Standards (#D6300 and #D6310, Zymo Research Corp., Irvine, USA) were
- incorporated and subjected to the identical process as the stool samples. The DNA yield and
- 416 purity were determined using the NanoDrop® ND -1000 (Nanodrop Technologies Inc.
- 417 Wilmington, USA).
- 418

419 Sequencing

- 420 Shotgun metagenomic sequencing was performed on all samples at the Integrated Microbiome
- 421 Research Resource (IMR, Dalhousie University, NS, Canada). A pooled library (max 96
- 422 samples per run) was prepared using the Illumina Nextera Flex Kit for MiSeq and NextSeq from
- 1 ng of each sample. Samples were then pooled onto a plate and sequenced on the Illumina
- 424 NextSeq 2000 platform using 150+150 bp paired-end P3 cells, generating 24M million raw
- 425 reads and 3.6 Gb of sequence per sample.

426 Statistics / computational analysis

427 Metagenome processing

- 428 Raw metagenomic sequence reads were processed using tools from the bioBakery as
- 429 previously described (Bonham et al. 2023; Beghini et al. 2021). Briefly, KneadData v0.10.0 was
- 430 used with default parameters to trim low-quality reads and remove human sequences (using
- 431 reference database hg37). Next, MetaPhlAn v3.1.0 (using database
- 432 mpa_v31_CHOCOPhIAn_201901) was used with default parameters to map microbial marker
- 433 genes to generate taxonomic profiles. Taxonomic profiles and raw reads were passed to
- 434 HUMAnN v3.7 to generate stratified functional profiles.
- 435

436 Microbial community analysis

- 437 Principal coordinates analysis was performed in the julia programming language (Bezanson et
- 438 al. 2012) using the Microbiome.jl package (Bonham et al. 2021). Bray-Curtis dissimilarity
- 439 (Distances.jl) was calculated across all pairs of samples, filtering for species-level classification.
- 440 Classical multidimensional scaling was performed on the dissimilarity matrix
- 441 (MultivariateStats.jl), and axes with negative eigenvalues were discarded.
- 442

443 Feature Set Enrichment Analysis (FSEA)

- 444 Potentially neuroactive genesets were extracted from Supplementary Dataset 1 from (Valles-
- 445 Colomer et al. 2019). Gut-brain modules provide Kegg Orthologue IDs (KOs), which were
- 446 mapped to UniRef90 IDs using the utility mapping file provided with HUMAnN v3.1. For each

447 stool / VEP pair, logistic regression (LR) was performed linking the presence of absence of that

UniRef in a sample with each VEP feature (N1, P1, and N2 latencies and amplitudes),

449 controlling for the age at which the stool sample was collected, the number of retained VEP

trials, and the difference in age between the stool collection and VEP measurement. For

451 concurrently collected stool and VEP comparisons (Figure 2), subjects whose stool collection

and VEP measurements were more than 2 months apart were excluded.

453

454 (1) UniRef ~ vep + age_months + n_trials + age_diff

455

456 FSEA was performed on each geneset that had at least 5 members in each comparison group

457 according to the procedure set out in Subramanian *et. al.* (2005)(Subramanian et al. 2005).

458 Briefly, enrichment scores (ES) are calculated based on the rank-order of z-statistics from the

LR for each UniRef. A permutation test was then performed where the ES for 5000 random

samples of ranks of the same length as the gene set are calculated, and the pseudo-p value is

the number fraction of permutations where the permutation ES has a greater absolute value

- 462 than the true ES.
- 463

464 Benjamini-Hochberg FDR correction was performed separately on all concurrently tested

465 geneset / VEP feature combinations, and all longitudinal geneset / VEP feature combinations.

466 Corrected p-values (q values) less than 0.2 were considered statistically significant.

467 References

Aburto, María R., and John F. Cryan. 2024. "Gastrointestinal and Brain Barriers: Unlocking
Gates of Communication across the Microbiota–Gut–Brain Axis." *Nature Reviews Gastroenterology & Hepatology* 21 (4): 222–47. https://doi.org/10.1038/s41575-02300890-0.

472 Agus, Allison, Julien Planchais, and Harry Sokol. 2018. "Gut Microbiota Regulation of
473 Tryptophan Metabolism in Health and Disease." *Cell Host & Microbe* 23 (6): 716–24.
474 https://doi.org/10.1016/j.chom.2018.05.003.

Ahmed, Hany, Quentin Leyrolle, Ville Koistinen, Olli Kärkkäinen, Sophie Layé, Nathalie
Delzenne, and Kati Hanhineva. 2022. "Microbiota-Derived Metabolites as Drivers of
Gut–Brain Communication." *Gut Microbes* 14 (1): 2102878.
https://doi.org/10.1080/19490976.2022.2102878

- 478 https://doi.org/10.1080/19490976.2022.2102878.
- Ahrens, Angelica P., Tuulia Hyötyläinen, Joseph R. Petrone, Kajsa Igelström, Christian D.
 George, Timothy J. Garrett, Matej Orešič, Eric W. Triplett, and Johnny Ludvigsson.
 2024. "Infant Microbes and Metabolites Point to Childhood Neurodevelopmental
 Disorders." *Cell* 187 (8): 1853-1873.e15. https://doi.org/10.1016/j.cell.2024.02.035.
- Bäckhed, Fredrik, Josefine Roswall, Yangqing Peng, Qiang Feng, Huijue Jia, Petia KovatchevaDatchary, Yin Li, et al. 2015. "Dynamics and Stabilization of the Human Gut Microbiome
 during the First Year of Life." *Cell Host & Microbe* 17 (5): 690–703.
 https://doi.org/10.1016/j.chom.2015.04.004.
- Baj, Andreina, Elisabetta Moro, Michela Bistoletti, Viviana Orlandi, Francesca Crema, and
 Cristina Giaroni. 2019. "Glutamatergic Signaling Along The Microbiota-Gut-Brain Axis."
 International Journal of Molecular Sciences 20 (6): 1482.
- 490 https://doi.org/10.3390/ijms20061482.
- 491 Beghini, Francesco, Lauren J McIver, Aitor Blanco-Míguez, Leonard Dubois, Francesco

492 Asnicar, Sagun Maharjan, Ana Mailyan, et al. 2021. "Integrating Taxonomic, Functional, 493 and Strain-Level Profiling of Diverse Microbial Communities with bioBakery 3." Elife 10 494 (May). https://doi.org/10.7554/eLife.65088. 495 Bezanson, Jeff, Stefan Karpinski, Viral B Shah, and Alan Edelman. 2012. "Julia: A Fast 496 Dynamic Language for Technical Computing," September. 497 http://arxiv.org/abs/1209.5145. 498 Bonham, Kevin, Guilherme Fahur Bottino, Shelley Hoeft McCann, Jennifer Beauchemin, 499 Elizabeth Weisse, Fatoumata Barry, Rosa Cano Lorente, et al. 2023. "Gut-Resident 500 Microorganisms and Their Genes Are Associated with Cognition and Neuroanatomy in 501 Children." Science Advances 9 (51): eadi0497. https://doi.org/10.1126/sciadv.adi0497. 502 Bonham, Kevin, Annelle Kavisire, Anika Luo, and Vanja Klepac-Ceraj. 2021. "Microbiome.Jl and 503 BiobakeryUtils.JI - Julia Packages for Working with Microbial Community Data." Journal 504 of Open Source Software 6 (67): 3876. https://doi.org/10.21105/joss.03876. Canipe, L. Grant, Michael Sioda, and Carol L. Cheatham. 2021. "Diversity of the Gut-505 506 Microbiome Related to Cognitive Behavioral Outcomes in Healthy Older Adults." 507 Archives of Gerontology and Geriatrics 96 (September):104464. 508 https://doi.org/10.1016/j.archger.2021.104464. 509 Chen, Tong, Daisuke Noto, Yasunobu Hoshino, Miho Mizuno, and Sachiko Miyake. 2019. 510 "Butyrate Suppresses Demyelination and Enhances Remyelination." Journal of 511 Neuroinflammation 16 (1): 165. https://doi.org/10.1186/s12974-019-1552-y. 512 Collins, Stephen M., Michael Surette, and Premysl Bercik. 2012. "The Interplay between the Intestinal Microbiota and the Brain." Nature Reviews Microbiology 10 (11): 735–42. 513 514 https://doi.org/10.1038/nrmicro2876. 515 Dalile, Boushra, Lukas Van Oudenhove, Bram Vervliet, and Kristin Verbeke. 2019. "The Role of 516 Short-Chain Fatty Acids in Microbiota-Gut-Brain Communication" 16 (8): 461–78. 517 https://doi.org/10.1038/s41575-019-0157-3. 518 Dean, Douglas C., Jonathan O'Muircheartaigh, Holly Dirks, Nicole Waskiewicz, Katie Lehman, 519 Lindsay Walker, Michelle Han, and Sean C. L. Deoni. 2014. "Modeling Healthy Male 520 White Matter and Myelin Development: 3 through 60 Months of Age." NeuroImage 84 521 (January):742-52. https://doi.org/10.1016/j.neuroimage.2013.09.058. 522 Deen, Ben, Hilary Richardson, Daniel D. Dilks, Atsushi Takahashi, Boris Keil, Lawrence L. 523 Wald, Nancy Kanwisher, and Rebecca Saxe. 2017. "Organization of High-Level Visual 524 Cortex in Human Infants." Nature Communications 8 (1): 13995. 525 https://doi.org/10.1038/ncomms13995. Dekkers, Koen F., Sergi Sayols-Baixeras, Gabriel Baldanzi, Christoph Nowak, Ulf Hammar, 526 527 Diem Nguyen, Georgios Varotsis, et al. 2022. "An Online Atlas of Human Plasma 528 Metabolite Signatures of Gut Microbiome Composition." Nature Communications 13 (1): 529 5370. https://doi.org/10.1038/s41467-022-33050-0. 530 Deng, Kui, Jin-jian Xu, Lugi Shen, Hui Zhao, Wanglong Gou, Fengzhe Xu, Yuanging Fu, et al. 531 2023. "Comparison of Fecal and Blood Metabolome Reveals Inconsistent Associations 532 of the Gut Microbiota with Cardiometabolic Diseases." Nature Communications 14 (1): 533 571. https://doi.org/10.1038/s41467-023-36256-y. 534 Ellis, Cameron T., Tristan S. Yates, Lena J. Skalaban, Vikranth R. Bejjanki, Michael J. Arcaro, and Nicholas B. Turk-Browne. 2021. "Retinotopic Organization of Visual Cortex in 535 536 Human Infants." Neuron 109 (16): 2616-2626.e6. 537 https://doi.org/10.1016/j.neuron.2021.06.004. 538 Erny, Daniel, Nikolaos Dokalis, Charlotte Mezö, Angela Castoldi, Omar Mossad, Ori 539 Staszewski, Maximilian Frosch, et al. 2021. "Microbiota-Derived Acetate Enables the 540 Metabolic Fitness of the Brain Innate Immune System during Health and Disease." Cell 541 Metabolism 33 (11): 2260-2276.e7. https://doi.org/10.1016/j.cmet.2021.10.010. Fagiolini, M., and T. K. Hensch. 2000. "Inhibitory Threshold for Critical-Period Activation in 542

F 40	
543	Primary Visual Cortex." Nature 404 (6774): 183–86. https://doi.org/10.1038/35004582.
544	Filpa, Viviana, Elisabetta Moro, Marina Protasoni, Francesca Crema, Gianmario Frigo, and
545	Cristina Giaroni. 2016. "Role of Glutamatergic Neurotransmission in the Enteric Nervous
546	System and Brain-Gut Axis in Health and Disease." Neuropharmacology 111
547	(December):14–33. https://doi.org/10.1016/j.neuropharm.2016.08.024.
548	Gilbert, Jack A., Martin J. Blaser, J. Gregory Caporaso, Janet K. Jansson, Susan V. Lynch, and
549	Roh Knight 2018 "Current Understanding of the Human Microbiome" Nature Medicine
550	24 (A): $392-400$ https://doi.org/10.1038/nm.4517
551	Hensch Takao K. Michela Eagiolini, Nobuko Mataga, Michael P. Struker, Steinunn
551	Packkockov and Shora E. Kash 1009 "Local CARA Circuit Control of Experience
552	Datekkeskov, and Sheld F. Kash. 1990. Local GADA Circuit Control of Experience-
553	Dependent Plasticity in Developing Visual Conex. Science 282 (5393). 1504–8.
554	nttps://doi.org/10.1126/science.282.5393.1504.
555	Janik, Rafal, Lynsie A. M. Thomason, Andrew M. Stanisz, Paul Forsythe, John Bienenstock,
556	and Greg J. Stanisz. 2016. "Magnetic Resonance Spectroscopy Reveals Oral
557	Lactobacillus Promotion of Increases in Brain GABA, N-Acetyl Aspartate and
558	Glutamate." <i>NeuroImage</i> 125 (January):988–95.
559	https://doi.org/10.1016/j.neuroimage.2015.11.018.
560	Kennedy, Elizabeth A., Katherine Y. King, and Megan T. Baldridge. 2018. "Mouse Microbiota
561	Models: Comparing Germ-Free Mice and Antibiotics Treatment as Tools for Modifying
562	Gut Bacteria." Frontiers in Physiology 9
563	https://www.frontiersin.org/articles/10.3389/fphys.2018.01534
564	Kiornes Lynne 2015 "Visual Development in Primates: Neural Mechanisms and Critical
504	Noipes, Lynne. 2013. Visual Development in Finnates. Neural Mechanisms and Childa
505	https://doi.org/10.1002/dpau.22276
500	nups.//doi.org/10.1002/dneu.22276.
567	Koenig, Jeremy E, Ayme Spor, Nicholas Scalione, Ashwana D Fricker, Jesse Stombaugh, Rob
568	Knight, Largus T Angenent, and Ruth E Ley. 2011. "Succession of Microbial Consortia in
569	the Developing Infant Gut Microbiome." Proceedings of the National Academy of
570	Sciences of the United States of America 108 Suppl 1 (March):4578–85.
571	https://doi.org/10.1073/pnas.1000081107.
572	Li, Jianrong, Judith C. Lin, Hong Wang, James W. Peterson, Barbara C. Furie, Bruce Furie,
573	Sara L. Booth, Joseph J. Volpe, and Paul A. Rosenberg. 2003. "Novel Role of Vitamin K
574	in Preventing Oxidative Injury to Developing Oligodendrocytes and Neurons." Journal of
575	Neuroscience 23 (13): 5816–26. https://doi.org/10.1523/JNEUROSCI.23-13-
576	05816.2003.
577	Lippé, S. M-S Roy, C Perchet, and M Lassonde, 2007, "Electrophysiological Markers of
578	Visuocortical Development " Cerebral Cortex 17 (1): 100–107
579	https://doi.org/10.1093/cercor/bhi130
580	Luco-Huitrón Dafael Derla Licalde Muñiz Benjamin Dineda, José Dedraza-Chaverrí, Camilo
500	Díos, and Varánica Dároz do la Cruz, 2012, "Quinclinic Acid: An Endogonous
201	Nourotovin with Multiple Terrete " Ovidetive Medicine and Collular Langevity
562	Neuroloxin with Multiple Targets. Oxidative Medicine and Celiular Longevity
583	2013:104024. https://doi.org/10.1155/2013/104024.
584	Lupori, Leonardo, Sara Cornuti, Raffaele Mazziotti, Elisa Borgni, Emerenziana Ottaviano,
585	Michele Dei Cas, Giulia Sagona, Tommaso Pizzorusso, and Paola Tognini. 2022. "The
586	Gut Microbiota of Environmentally Enriched Mice Regulates Visual Cortical Plasticity."
587	Cell Reports 38 (2): 110212. https://doi.org/10.1016/j.celrep.2021.110212.
588	Meyer, Katie, Anju Lulla, Kunal Debroy, James M. Shikany, Kristine Yaffe, Osorio Meirelles, and
589	Lenore J. Launer. 2022. "Association of the Gut Microbiota With Cognitive Function in
590	Midlife." JAMA Network Open 5 (2): e2143941.
591	https://doi.org/10.1001/jamanetworkopen.2021.43941.
592	Monachino, A D, K L Lopez, L J Pierce, and L J Gabard-Durnam. 2022. "The HAPPE plus
593	Event-Related (HAPPE+ER) Software: A Standardized Preprocessing Pipeline for

594 Event-Related Potential Analyses." Modeling Neural Development 57 (101140): 101140. 595 https://doi.org/10.1016/j.dcn.2022.101140. Parker, Aimée, Sonia Fonseca, and Simon R. Carding. 2019. "Gut Microbes and Metabolites as 596 597 Modulators of Blood-Brain Barrier Integrity and Brain Health." Gut Microbes 11 (2): 135-598 57. https://doi.org/10.1080/19490976.2019.1638722. 599 Rhee, Sang H., Charalabos Pothoulakis, and Emeran A. Mayer. 2009. "Principles and Clinical 600 Implications of the Brain-Gut-Enteric Microbiota Axis." Nature Reviews. 601 Gastroenterology & Hepatology 6 (5): 306–14. https://doi.org/10.1038/nrgastro.2009.35. 602 Subramanian, Aravind, Pablo Tamayo, Vamsi K. Mootha, Sayan Mukherjee, Benjamin L. Ebert, 603 Michael A. Gillette, Amanda Paulovich, et al. 2005. "Gene Set Enrichment Analysis: A 604 Knowledge-Based Approach for Interpreting Genome-Wide Expression Profiles." 605 Proceedings of the National Academy of Sciences 102 (43): 15545–50. 606 https://doi.org/10.1073/pnas.0506580102. 607 Takesian, Anne E., Luke J. Bogart, Jeff W. Lichtman, and Takao K. Hensch. 2018. "Inhibitory 608 Circuit Gating of Auditory Critical-Period Plasticity." Nature Neuroscience 21 (2): 218–27. 609 https://doi.org/10.1038/s41593-017-0064-2. Tavares, Rejane G., Carla I. Tasca, Candice E. S. Santos, Moacir Wajner, Diogo O. Souza, and 610 611 Carlos S. Dutra-Filho. 2000. "Quinolinic Acid Inhibits Glutamate Uptake into Synaptic 612 Vesicles from Rat Brain." NeuroReport 11 (2): 249. 613 Valles-Colomer, Mireia, Gwen Falony, Youssef Darzi, Ettje F Tigchelaar, Jun Wang, Raul Y 614 Tito, Carmen Schiweck, et al. 2019. "The Neuroactive Potential of the Human Gut 615 Microbiota in Quality of Life and Depression." Nature Microbiology 4 (4): 623–32. 616 https://doi.org/10.1038/s41564-018-0337-x. Wymore Brand, Meghan, Michael J. Wannemuehler, Gregory J. Phillips, Alexandra Proctor, 617 618 Anne-Marie Overstreet, Albert E. Jergens, Roger P. Orcutt, and James G. Fox. 2015. 619 "The Altered Schaedler Flora: Continued Applications of a Defined Murine Microbial 620 Community." ILAR Journal 56 (2): 169-78. https://doi.org/10.1093/ilar/ilv012. 621 Yassour, Moran, Tommi Vatanen, Heli Siljander, Anu-Maaria Hämäläinen, Taina Härkönen, 622 Samppa J Ryhänen, Eric A Franzosa, et al. 2016. "Natural History of the Infant Gut 623 Microbiome and Impact of Antibiotic Treatment on Bacterial Strain Diversity and 624 Stability." Science Translational Medicine 8 (343): 343ra81. 625 https://doi.org/10.1126/scitranslmed.aad0917. 626 Zieff, Michal R, Marlie Miles, Emmie Mbale, Emma Eastman, Lorna Ginnell, Steven C R Williams, Derek K Jones, et al. 2024. "Characterizing Developing Executive Functions in 627 the First 1000 Days in South Africa and Malawi: The Khula Study." Wellcome Open 628 629 Research 9 (March):157. https://doi.org/10.12688/wellcomeopenres.19638.1.